Mural Oncology plc
Mural Oncology plc (MURA): 7 pipeline candidates · ~10 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.9 months
D/E 0.19 · 0% dilution
Lead: Phase 3
7 candidates
N/A
N/A
A transparent, data-derived signal for Mural Oncology plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$60.6M
Quarterly Burn
$18.5M
Runway
9.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| alks 4230 | Phase 2 |
| mura-7012 | Preclinical |
| mura-8518 | Preclinical |
| nemvaleukin | Phase 3 |
| nemvaleukin alfa | Phase 3 |
| nemvaleukin alfa intravenous less frequent dosing | Phase 3 |
| topotecan | Phase 3 |
Frequently asked questions
How many drug candidates are in Mural Oncology plc's pipeline?
Mural Oncology plc (MURA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mural Oncology plc's lead drug candidate?
Mural Oncology plc's most advanced tracked candidate is alks 4230 (Phase 2) for Advanced Solid Tumors.
What is Mural Oncology plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mural Oncology plc has approximately 9.9 months of cash runway.
Who is the CEO of Mural Oncology plc?
Corporate Governance Committee is the chief executive officer of Mural Oncology plc (MURA).
Get the full picture on Mural Oncology plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.